pharmaceutical product liability
-
This article originally appeared in the November 2009 Drug, Device and Biotechnology Committee Newsletter.
**********
Since the adoption of the Fe...
-
The product liability arising due to the use of pharmaceuticals is a very sensitive issue in comparison with any other kind of product liability, sinc...
-
ONLY a handful of pharmaceutical product liability cases have been tried in Canada, with the leading case being a decision from the mid-1980s involvin...
-
On March 4, 2009, the U.S. Supreme Court delivered its highly
anticipated decision in Wyeth v. Levine, upholding the
plaintiff's $7.4 million product ...
-
ENGLAND was one of the first European Union ("EU") countries to introduce specific procedural provisions for "group actions" seeking recovery of damag...
-
- Ryan P. Ehlis; Angie Moreno, Individually, and as Surviving Parents of Tyra Lynn Ehlis, Deceased, Appellants/Cross Appellees, v. Shire Richwood, Inc., Now Known as Shire Us, Inc., Appellee/Cross Appellant, Shire Pharmaceuticals Group, Plc, Defendant. Product Liability Advisory Council, Incorporated; Pharmaceutical Research and Manufacturers of America, Amici on Behalf of Appellee., 367 F.3d 1013 (8th Cir. 2004)
Jessica R. Dart, argued, Los Angeles, California (Arnold Anderson Vickery, Houston, Texas, and Earl Landers Vickery, Austin, Texas on the brief), for ...
-
On March 4, 2009, the U.S. Supreme Court delivered its highly anticipated decision in Wyeth v. Levine, upholding the plaintiff's $7.4 million product ...
-
A federal jury in St. Louis ruled for the defense in a pharmaceutical product liability case.
Attorneys for plaintiff John Brodie, of Arnold, alleged that defendant Novartis Pharmaceuticals Corp. didn't provide sufficient warning to consumers and doctors about the risk of osteonecrosis of the jaw associated with the drug Zometa. Brodie, who was suffering from prostate cancer, was being treated with Zometa when he developed ONJ, also called jaw death, according to court filings.
-
GERMANY improved the legal situation of pharmaceutical products liability plaintiffs by enacting two laws: 1) the second Pharmaceutical Act of August ...
-
Plaintiffs' lawyers are gearing up for a slew of pharmaceutical product liability trials in 2010.
While no case has the magnitude of the massive $4.85 billion Vioxx settlement in 2007, the trials represent a welcome return to courtroom action on the pharmaceutical front for plaintiffs' lawyers.